|
| ID |
DDInter1157 |
| Drug Type |
small molecule |
| Molecular Formula |
C17H25N3O5S |
| Molecular Weight |
383.469
|
| Description |
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
|
| ATC Classification |
J01DH02
J01DH52
|
| IUPAC Name |
(4R,5S,6S)-3-{[(3S,5S)-5-(Dimethylcarbamoyl)Pyrrolidin-3-Yl]Sulfanyl}-6-[(1R)-1-Hydroxyethyl]-4-Methyl-7-Oxo-1-Azabicyclo[3.2.0] |
| InChI |
Inchi=1S/C17H25N3O5S/C1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/H7-12,18,21H,5-6H2,1-4H3,(H,24,25)/T7-,8-,9+,10+,11-,12-/M1/S1 |
| InChI Key |
DMJNNHOOLUXYBV-PQTSNVLCSA-N |
| Canonical SMILES |
[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H] |
| Useful Links |
DrugBank
ChEMBL
|